Abstract:Despite extensive research, the exact mechanisms involved in colorectal cancer (CRC) etiology and pathogenesis remain unclear. This study aimed to examine the correlation between tumor-associated alternative splicing (AS) events and tumor immune infiltration (TII) in CRC. We analyzed transcriptome profiling and clinical CRC data from The Cancer Genome Atlas (TCGA) database and lists of AS-related and immune-related signatures from the SpliceSeq and Innate databases, respectively to develop and validate a risk model of differential AS events and subsequently a TII risk model. We then conducted a two-factor survival analysis to study the association between TII and AS risk and evaluated the associations between immune signatures and six types of immune cells based on the TIMER database. Subsequently, we studied the distribution of six types of TII cells in high- and low-risk groups for seven AS events and in total. We obtained the profiles of AS events/genes for 484 patients, which included 473 CRC tumor samples and 41 corresponding normal samples, and detected 22581 AS events in 8122 genes. Exon Skip (ES) (8446) and Mutually Exclusive Exons (ME) (74) exhibited the most and fewest AS events, respectively. We then classified the 433 patients with CRC into low-risk (n = 217) and high-risk (n = 216) groups based on the median risk score in different AS events. Compared with patients with low-risk scores (mortality = 11.8%), patients with high-risk scores were associated with poor overall survival (mortality = 27.6%). The risk score, cancer stage, and pathological stage (T, M, and N) were closely correlated with prognosis in patients with CRC ( P < 0.001). We identified 6479 differentially expressed genes from the transcriptome profiles of CRC and intersected 468 differential immune-related signatures. High-AS-risk and high-TII-risk predicted a poor prognosis in CRC. Different AS types were associated with different TII risk characteristics. Alternate Acceptor site (AA) and Alternate Promoter (AP) events directly affected the concentration of CD4T cells, and the level of CD8T cells was closely correlated with Alternate Terminator (AT) and Exon Skip (ES) events. Thus, the concentration of CD4T and CD8T cells in the CRC immune microenvironment was not specifically modulated by AS. However, B cell, dendritic cell, macrophage, and neutrophilic cell levels were strongly correlated with AS events. These results indicate adverse associations between AS event risk levels and immune cell infiltration density. Taken together, our findings show a clear association between tumor-associated alternative splicing and immune cell infiltration events and patient outcome and could form a basis for the identification of novel markers and therapeutic targets for CRC and other cancers in the future.

RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

AEP promotes aberrant RNA splicing through DDX3X cleavage in solid tumors

AEP-cleaved DDX3X Induces Alternative RNA Splicing Events to Mediate Cancer Cell Adaptation in Harsh Microenvironments.

SEC23A Regulated by Splicing Factor EIF3A may be Involved in the Development of Cervical Squamous Cell Cancer via Adherens Junction Pathway

SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes

Hnrnp A1/A2 And Sf2/Asf Regulate Alternative Splicing Of Interferon Regulatory Factor-3 And Affect Immunomodulatory Functions In Human Non-Small Cell Lung Cancer Cells

Epigenetic Regulation of Alternative Splicing.

Alterations of RNA splicing patterns in esophagus squamous cell carcinoma

Alternative Splicing and Isoforms Correlate with Immune Subpopulations and Molecular Signatures of Uveal Melanoma

SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis

Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer

RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma

Alternative splicing regulation by tumor suppressing subtransferable candidate 4: a pathway to tumor suppression

Correlations Between the Characteristics of Alternative Splicing Events, Prognosis, and the Immune Microenvironment in Breast Cancer

The interplay between non-coding RNAs and alternative splicing: from regulatory mechanism to therapeutic implications in cancer

RNA splicing dysregulation and the hallmarks of cancer

Systemic Analysis of RNA Alternative Splicing Signals Related to the Prognosis for Head and Neck Squamous Cell Carcinoma

Mechanisms of non-coding RNA-modulated alternative splicing in cancer

N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma

Survival-associated alternative splicing signatures in esophageal carcinoma